10:28 AM EDT, 06/03/2024 (MT Newswires) -- Agios Pharmaceuticals ( AGIO ) said Monday a phase 3 trial of mitapivat in adults with transfusion-dependent thalassemia achieved its primary endpoint of transfusion reduction response.

The study also achieved "statistical significance" for all key secondary endpoints assessing additional measures of decrease of transfusion burden compared with placebo, the company said.

Agios said it plans to file a marketing application in the US with results from the latest trial and a previous one by the end of 2024.

It also plans to file marketing applications in Europe and the Gulf Cooperation Council countries, it said.

Agios shares were rising past 14% in recent trading.

Price: 42.00, Change: +5.66, Percent Change: +15.58